Chi-Med Roll Continues With Positive Fruquintinib Phase III Data

Chi-Med's China-focused strategy is paying off with positive Phase III top-line results for its home-grown VEGF inhibitor fruquintinib, keeping it on track to for a filing this year. But competition looms.

China globe

The first look at Phase III data for Chi-Med (Hutchison China MediTech Ltd.)'s new highly selective VEGF inhibitor fruquintinib show encouraging efficacy on both primary and secondary endpoints in third-line colorectal cancer, leading the way to a filing in China mid-year and a possible launch in 2018.

Top-line results from Chi-Med's first pivotal trial, FRESCO, in 416 patients with locally advanced or metastatic colorectal cancer in China...

More from Clinical Trials

More from R&D